DMAC - DiaMedica Therapeutics Inc

DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company is headquartered in Minneapolis, Minnesota.

52W High

$6.82

52W Low

$3.19

MA Status:

50D: Above 200D: Above

Beta (~1 neutral, <0.9 lower risk)

1.40

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-0.96

EV/Revenue (<3 favorable)

N/A

P/S (TTM) (<3 favorable)

N/A

P/B (<3 favorable)

11.68

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

33.51%

Institutions (25–75% balanced)

37.65%

Shares Outstanding

51,689,000

Float

27,519,700

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

Gross Profit (TTM)

EPS (TTM)

-0.69

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-0.73%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Bearish momentum

Value

0.2636

0.2220

Trend

Rising

Signal Cross

No cross

As of

Sep. 05, 2025